burapitant burapitant burapitant (ssr-240,600) is a drug developed by sanofi-aventis which was one of the first compounds developed that acts as a potent and selective antagonist for the nk1 receptor. while burapitant itself did not proceed beyond early clinical trials and was never developed for clinical use in humans, promising animal results from this and related compounds have led to a number of novel drugs from this class that have now been introduced into medical use. burapitantclinical dataatc codenoneidentifiers iupac name 2-acetyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl]piperidin-4-yl]-2-methylpropanamide cas number537034-22-3 ypubchem cid23649599chemspider26519428uniie35sk332mscomptox dashboard (epa)dtxsid10968465 chemical and physical dataformulac31h35cl2f6n3o3molar mass682.53 g·mol−13d model (jsmol)interactive image smiles cc(c)(c1ccn(cc1)cc2(cn(cco2)c(=o)cc3=cc(=cc(=c3)c(f)(f)f)c(f)(f)f)c4=cc(=c(c=c4)cl)cl)c(=o)n inchi inchi=1s/c31h35cl2f6n3o3/c1-28(2,27(40)44)20-5-8-41(9-6-20)10-7-29(21-3-4-24(32)25(33)17-21)18-42(11-12-45-29)26(43)15-19-13-22(30(34,35)36)16-23(14-19)31(37,38)39/h3-4,13-14,16-17,20h,5-12,15,18h2,1-2h3,(h2,40,44)/t29-/m0/s1key:zlnyucxxsddifu-ljaqvgfwsa-n